Conference examines role of chromosome changes in cancer

October 28, 2005

The University of Chicago will present a conference on "Chromosomes and Cancer: From Translocations to Targeted Therapies," on Mon., Nov. 7, 2005, at Ida Noyes Hall, 1212 E. 59th St., Chicago, IL.

The conference, sponsored by the University of Chicago Cancer Research Center and the Section of Hematology/Oncology of the Department of Medicine at the University of Chicago, will update participants on progress in understanding cancer and examine the latest advances in targeted therapies for leukemia and other cancers -- treatments rooted in Rowley's fundamental discoveries.

It will feature many of the world's leading experts on the genetics of leukemia and lymphoma and the development of targeted therapies based on genetic understanding of cancer, including Brian Drucker, M.D., who developed Gleevec based on a 1972 discovery by Rowley, and Clara Bloomfield, M.D., who was among the first to suggest, and later show, that adult acute leukemia was curable with chemotherapy.

In the early 1970s, Rowley, the Blum-Riese Distinguished Service Professor of Medicine, Molecular Genetics and Cell Biology, Human Genetics, and the Committees on Genetics and Cancer Biology, at the University of Chicago -- who turned 80 in April -- produced the first solid evidence that cancer was essentially a genetic disorder.

In 1972, she discovered the first chromosome "translocation," an exchange of small pieces of DNA between chromosomes 8 and 21 in patients with acute myeloblastic leukemia. Later that same year, she found that something similar happened in patients with chronic myelogenous leukemia; a crucial segment of chromosome 22 broke off and moved to chromosome 9, where it did not belong. At the same time, a tiny piece of chromosome 9, which included an important cancer-causing gene, had moved to the breakpoint on chromosome 22. Because of this exchange, genes that regulated cell growth and division were no longer located in their normal positions on the chromosome.

Rowley and colleagues subsequently identified other translocations tied to specific malignancies, such as the 14;18 translocation seen in follicular lymphoma, and the 15;17 translocation that causes acute promyelocytic leukemia (APL). Quickly picking up on her lead that certain translocations defined specific forms of cancer, scientists around the world joined the search for chromosomes that either exchanged genetic material or in some cases lost it altogether. Others used the translocations as road maps to find specific cancer causing genes, opening up the current era of cancer genetics, accurate diagnostic techniques, and precisely targeted therapies.

Rowley has received many awards for her discoveries, including the Lasker Prize and the National Medal of Science, the nation's highest scientific honor, in 1998, and the Dorothy Landon-AACR Prize for Translational Research in 2005. She is also an outspoken member of the President's Council on Bioethics.

Program, Monday, November 7

8:00AM Introduction/Welcome:
Everett Vokes, M.D., and Olufunmilayo Olopade, M.B.B.S., FACP

Session I: From Translocations to Targeted Therapies
Chairs: Manuel Diaz, M.D., and Elizabeth Shima Rich, M.D., Ph.D.

8:20 Michelle Le Beau, Ph.D., Professor of Medicine and Director, University of Chicago Cancer Research Center.

8:40 James Vardiman, M.D., Professor of Medicine and Pathology, Director of Clinical Hematology Laboratory, University of Chicago.

9:00 Clara Bloomfield, M.D., Professor of Cancer Research, Comprehensive Cancer Center, James Cancer Hospital & Solove Research Institute, Ohio State University.

9:30 Brian Druker, M.D., Professor of Medicine, Oregon Health Sciences University. . Session II: Modeling Human Hematopoietic Disease
Chairs: Giuseppina Nucifora, Ph.D., and Olatoyosi Odenike, M.D.

10:30 Gary Gilliland, M.D., Ph.D., Professor of Medicine, Harvard Medical School, and Director of the Leukemia Program at the Dana-Farber/Harvard Cancer Center.

11:00 James Downing, M.D., Scientific Director and Chair of Pathology; Co-Leader of the Hematological Malignancies Program and Director of the Molecular Pathology Laboratory, St. Jude Children's Research Hospital.

11:30 Timothy Ley, M.D., Wolff Professor of Medicine and Genetics, Washington University School of Medicine, St. Louis, MO, and Associate Director for Basic Research at the Siteman Cancer Center.

12:00PM Jeffrey Trent, Ph.D., President, Scientific Director, and Senior Investigator of the Genetic Basis of Human Disease Division, Translational Genomics Research Institute (TGen), Phoenix, Arizona.

Session III: Beyond Translocations to New Targets
Chair: Feyruz Rassool, Ph.D.

1:30 Nancy Speck, Ph.D., Professor of Biochemistry and the Associate Director for Basic Science at the Norris Cotton Cancer Center.

2:00 Stefan Bohlander, M.D., Professor, Ludwig-Maximilians University, Munich, Germany.

2:30 Donald Small, M.D., Ph.D., Professor of Oncology and Pediatrics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University.

3:00 Lucy Godley, M.D., Ph.D., Assistant Professor of Medicine, University of Chicago.

Session IV: Genomic Approaches to Cancer Classification
Chair: Nancy Zeleznik-Le, Ph.D.

4:00 Michael Thirman, M.D., Associate Professor of Medicine, University of Chicago.

4:30 Ruud Delwel, Ph.D., Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.

5:00 Janet Rowley, M.D., Blum-Riese Distinguished Service Professor of Medicine, Molecular Genetics and Cell Biology, Human Genetics, and the Committees on Genetics and Cancer Biology, University of Chicago.
-end-
For information on how to register for the conference, go to: http://www.uchicago.edu/bsd/cme/2005/RowleySymposiumBrochure.pdf

University of Chicago Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.